Jane Perlmutter

17.1k total citations · 3 hit papers
66 papers, 3.6k citations indexed

About

Jane Perlmutter is a scholar working on Oncology, Education and Cancer Research. According to data from OpenAlex, Jane Perlmutter has authored 66 papers receiving a total of 3.6k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 15 papers in Education and 15 papers in Cancer Research. Recurrent topics in Jane Perlmutter's work include Ethics in Clinical Research (12 papers), HER2/EGFR in Cancer Research (8 papers) and Statistical Methods in Clinical Trials (8 papers). Jane Perlmutter is often cited by papers focused on Ethics in Clinical Research (12 papers), HER2/EGFR in Cancer Research (8 papers) and Statistical Methods in Clinical Trials (8 papers). Jane Perlmutter collaborates with scholars based in United States, Canada and France. Jane Perlmutter's co-authors include Anthony D. Pellegrini, Lee Galda, Gene H. Brody, Meredith M. Regan, W. Fraser Symmans, Lisa A. Carey, Daniel F. Hayes, Charles M. Perou, M. Elizabeth H. Hammond and Mitch Dowsett and has published in prestigious journals such as Journal of Clinical Oncology, Psychological Bulletin and PLoS ONE.

In The Last Decade

Jane Perlmutter

62 papers receiving 3.5k citations

Hit Papers

Estrogen and Progesterone Receptor Testing in Breast Canc... 2018 2026 2020 2023 2020 2018 2022 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update
    2020 851 citations Kimberly H. Allison, M. Elizabeth H. Hammond et al. Journal of Clinical Oncology profile →
  2. Radiation therapy for the whole breast: Executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based guideline
    2018 395 citations Jane Perlmutter et al. profile →
  3. Systemic Therapy for Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: ASCO Guideline Update
    2022 116 citations Sharon H. Giordano, Maria Alice Franzoi et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jane Perlmutter United States 24 1.9k 1.3k 848 547 367 66 3.6k
Brenda F. Kurland United States 43 1.1k 0.6× 706 0.5× 958 1.1× 2.3k 4.3× 357 1.0× 122 5.5k
Ian Hay United States 60 1.8k 0.9× 425 0.3× 714 0.8× 1.1k 2.0× 1.2k 3.2× 229 13.5k
Mary Beattie United States 28 1.0k 0.5× 532 0.4× 406 0.5× 111 0.2× 412 1.1× 67 2.8k
Sylvain Baruchel Canada 42 1.6k 0.8× 1.2k 0.9× 1.0k 1.2× 149 0.3× 390 1.1× 134 5.7k
Neil E. Martin United States 36 1.4k 0.8× 373 0.3× 1.8k 2.2× 344 0.6× 187 0.5× 165 4.0k
Lindsay A. Williams United States 17 1.2k 0.7× 715 0.5× 280 0.3× 167 0.3× 105 0.3× 59 2.1k
Daniel Hayes United Kingdom 22 2.5k 1.4× 1.3k 1.0× 333 0.4× 94 0.2× 267 0.7× 77 4.5k
Daniel C. West United States 29 450 0.2× 211 0.2× 885 1.0× 181 0.3× 364 1.0× 85 4.4k
George Hruby Australia 37 1.3k 0.7× 317 0.2× 2.8k 3.3× 1.2k 2.2× 105 0.3× 159 4.7k
Linda Bradley United States 29 403 0.2× 380 0.3× 334 0.4× 77 0.1× 222 0.6× 87 3.4k

Countries citing papers authored by Jane Perlmutter

Since Specialization
Citations

This map shows the geographic impact of Jane Perlmutter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jane Perlmutter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jane Perlmutter more than expected).

Fields of papers citing papers by Jane Perlmutter

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jane Perlmutter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jane Perlmutter. The network helps show where Jane Perlmutter may publish in the future.

Co-authorship network of co-authors of Jane Perlmutter

This figure shows the co-authorship network connecting the top 25 collaborators of Jane Perlmutter. A scholar is included among the top collaborators of Jane Perlmutter based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jane Perlmutter. Jane Perlmutter is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Marron, Thomas U., Jason J. Luke, Brianna Hoffner, et al.. (2025). A SITC vision: adapting clinical trials to accelerate drug development in cancer immunotherapy. Journal for ImmunoTherapy of Cancer. 13(3). e010760–e010760. 1 indexed citations
2.
3.
Magbanua, Mark Jesus M., Rosalyn W. Sayaman, Lamorna Brown Swigart, et al.. (2024). Cell-free DNA Concentration as a Biomarker of Response and Recurrence in HER2-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy. Clinical Cancer Research. 30(11). 2444–2451. 2 indexed citations
4.
Nanda, Rita, Ronald Cohen, Zoe Quandt, et al.. (2024). Incidence and time to onset of immunotherapy-related adrenal insufficiency in the I-SPY2 trial.. Journal of Clinical Oncology. 42(16_suppl). 584–584.
5.
Perlmutter, Jane, Susie Brain, Deborah Collyar, et al.. (2023). Advocate involvement in Clinical Trials: Lessons from the Patient-centric I-SPY2 Breast Cancer Trial. Medical Research Archives. 11(7.2). 2 indexed citations
6.
Giordano, Sharon H., Maria Alice Franzoi, Sarah Temin, et al.. (2022). Systemic Therapy for Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: ASCO Guideline Update. Journal of Clinical Oncology. 40(23). 2612–2635. 116 indexed citations breakdown →
7.
Ramakrishna, Naren, Carey K. Anders, Nancy U. Lin, et al.. (2022). Management of Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases: ASCO Guideline Update. Journal of Clinical Oncology. 40(23). 2636–2655. 41 indexed citations
8.
Allison, Kimberly H., M. Elizabeth H. Hammond, Mitch Dowsett, et al.. (2020). Estrogen and Progesterone Receptor Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Guideline Update. Archives of Pathology & Laboratory Medicine. 144(5). 545–563. 215 indexed citations
9.
Zick, Suzanna M., Judith M. Fouladbakhsh, Heather Greenlee, et al.. (2018). Integrative Oncology Scholars Program: A Model for Integrative Oncology Education. The Journal of Alternative and Complementary Medicine. 24(9-10). 1018–1022. 12 indexed citations
10.
Nanda, Rita, Minetta C. Liu, Christina Yau, et al.. (2017). Pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer (BC): Results from I-SPY 2.. Journal of Clinical Oncology. 35(15_suppl). 506–506. 158 indexed citations
11.
Giordano, Sharon H., Sarah Temin, Jeffrey J. Kirshner, et al.. (2014). Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology. 32(19). 2078–2099. 258 indexed citations
12.
13.
Flynn, Kathryn E., Judith M. Kramer, Devon K. Check, et al.. (2013). Using Central IRBs for Multicenter Clinical Trials in the United States. PLoS ONE. 8(1). e54999–e54999. 42 indexed citations
14.
Chauhan, C., et al.. (2011). Translational Breast Cancer Research Consortium (TBCRC) Patient Advocate Working Group (PAWG): An approach to research advocacy.. Journal of Clinical Oncology. 29(15_suppl). e19539–e19539. 1 indexed citations
15.
Perlmutter, Jane, et al.. (1995). Learning through "Play" As Well As "Work" in the Primary Grades.. Young children. 50(5). 14–21. 14 indexed citations
16.
Perlmutter, Jane, et al.. (1993). Sociodramatic Play; A Stage for Practicing Literacy.. Dimensions of early childhood. 21(4). 13–1. 1 indexed citations
17.
Perlmutter, Jane. (1990). Fostering Children's Fantasy Play.. 18(3). 23–30. 1 indexed citations
18.
Pellegrini, Anthony D., Jane Perlmutter, Lee Galda, & Gene H. Brody. (1990). Joint Reading between Black Head Start Children and Their Mothers. Child Development. 61(2). 443–443. 109 indexed citations
19.
Pellegrini, Anthony D. & Jane Perlmutter. (1988). Rough-and-Tumble Play on the Elementary School Playground.. Young children. 43(2). 14–17. 14 indexed citations
20.
Perlmutter, Jane, et al.. (1976). The role of semantic knowledge in retrieval from episodic long-term memories: Implications for a model of retrieval. Memory & Cognition. 4(4). 361–368. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Brenda F. Kurland Breakdown of academic impact, for papers by Ian Hay Breakdown of academic impact, for papers by Mary Beattie Breakdown of academic impact, for papers by Sylvain Baruchel Breakdown of academic impact, for papers by Neil E. Martin Breakdown of academic impact, for papers by Lindsay A. Williams Breakdown of academic impact, for papers by Daniel Hayes Breakdown of academic impact, for papers by Daniel C. West Breakdown of academic impact, for papers by George Hruby Breakdown of academic impact, for papers by Linda Bradley
Rankless by CCL
2026